Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Ultragenyx Pharmaceutical Inc..
Ultragenyx Pharmaceutical Inc. is a company.
Key people at Ultragenyx Pharmaceutical Inc..
Key people at Ultragenyx Pharmaceutical Inc..
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare and ultra-rare genetic diseases.[1][2] Founded in 2010 and headquartered in Novato, California, it addresses unmet medical needs by advancing treatments like Crysvita® (burosumab) for X-linked hypophosphatemia (XLH) and Mepsevii™ (vestronidase alfa) for Mucopolysaccharidosis VII (MPS VII), serving small patient populations with severe conditions.[1][2][3] The company boasts one of the largest and most diverse pipelines in rare disease, with recent Phase 3 data for setrusumab (UX143) in osteogenesis imperfecta, driving growth from clinical-stage to commercial operations.[1][2]
Ultragenyx was founded in 2010 by Emil D. Kakkis, M.D., Ph.D., a physician and researcher with extensive expertise in genetic diseases, motivated by the urgent need for novel therapies in rare and ultra-rare diseases.[1][2][4] Kakkis's background in rare disease research shaped the company's direction from the start, establishing headquarters in Novato, California.[1][4] Key milestones include its 2014 IPO raising $126 million to fund clinical development, followed by the first FDA approval of Mepsevii™ in 2017 and Crysvita® in 2018, marking its shift to a commercial-stage biotech with revenue from orphan drugs.[1][3]
Ultragenyx rides the wave of precision medicine and orphan drug development, targeting rare genetic diseases where traditional big pharma hesitates due to small markets but high unmet needs.[1][3] Timing aligns with regulatory incentives like FDA breakthrough designations and orphan drug exclusivity, amplified by advances in gene therapy and biologics.[1][2] Market forces favoring it include growing venture interest in biotech pipelines and partnerships for global reach, as seen with Crysvita®'s success.[3] It influences the ecosystem by validating rare disease as a viable commercial space, inspiring focused biotechs and fostering collaborations that accelerate therapies to patients.[1][3]
Ultragenyx is poised for expansion with its diverse pipeline, including setrusumab's Phase 3 results signaling potential new approvals in bone disorders.[2] Trends like AI-driven drug discovery and expanded gene therapies will shape its trajectory, alongside regulatory tailwinds for orphans. Its influence may grow through more blockbusters and partnerships, solidifying leadership in rare disease while scaling revenue from current flagships like Crysvita®.[1][2][3]
